Tamoxifen (TAM) is commonly used in HR+ breast cancer with more than 50% effectiveness [5], whereas the effectiveness of TAM in estrogen receptor negative (ER−) breast cancer is reportedly about 7% [6]. The gene discussed is ESR1; the disease is breast carcinoma.